ARTI-guided TB outreach concentrates yield where infection pressure is highest
A mathematical modeling study from Blantyre, Malawi, suggests that active case finding for tuberculosis can become more efficient when it is steered by neighborhood-level estimates of the annual risk of TB infection, or ARTI, derived from Mycobacterium tuberculosis immunoreactivity surveys in children younger than 5 years. The core question was straightforward but operationally difficult: where should health workers go when resources are too limited to screen an entire city with equal intensity?
The model compared three strategies across 33 urban neighborhoods: passive case finding alone, passive case finding plus untargeted active case finding, and passive case finding plus ARTI-guided targeted active case finding. In the targeted approach, outreach covered half of the study population and was concentrated in areas with higher estimated ARTI. Within that design, the model estimated that targeted outreach would identify 80% of all individuals with tuberculosis. For a program that has to choose between breadth and precision, this is the kind of efficiency gain that changes how field teams are deployed.
Cost per DALY fell with targeting, but the modeled program still strained thresholds
The health gains were substantial in the modeled cohort. Compared with passive case finding alone, untargeted active case finding was estimated to improve life expectancy by 3.3 years, with a 95% credible interval of 1.7 to 5.4 years, for individuals with TB disease. Yet the price of blanketing a wider population was high. Under the main analysis, targeted active case finding achieved a lower cost per disability-adjusted life year averted than untargeted outreach: US$400, with a 95% credible interval of US$20 to US$1,000, versus US$700, with a 95% credible interval of US$100 to US$1,500.
Those numbers move in the right direction, but they do not erase the budget problem. In the main analysis, both strategies exceeded available cost-effectiveness thresholds for Malawi. This is a crucial distinction for ministries of health and district programs: better efficiency does not automatically convert into affordability when the underlying intervention remains expensive relative to local thresholds. The model also found that cost-effectiveness improved when assumptions favored higher TB prevalence or a greater reduction in secondary transmission, reflecting the epidemiologic logic that detection becomes more valuable when each missed case is more likely to generate downstream infections.
Why child immunoreactivity may be a useful surveillance signal
The appeal of ARTI-guided targeting rests on transmission biology. Immunoreactivity surveys in young children offer a proxy for recent community exposure to Mycobacterium tuberculosis, and neighborhoods with higher infection pressure among children are likely to harbor more ongoing transmission. If that relationship holds, then pediatric immunoreactivity can serve as a geographic marker for where adult TB burden is concentrated, allowing outreach teams to prioritize the places where undiagnosed disease is more likely to be found.
This approach is attractive because TB programs rarely operate with perfect prevalence maps. Passive case finding depends on who comes to care, while untargeted active case finding consumes staff time, diagnostics, transport, and community engagement across a broad population regardless of risk. The modeled strategy tries to align surveillance with action, using a marker of recent transmission to guide where case-finding teams should be sent first. In a city with limited field capacity, that alignment may matter as much as the screening tool itself.
Modeling gains were real, but the uncertainty sits inside the surveillance tool itself
The study’s conclusions are deliberately bounded by the assumptions needed to build the model. The relationship between ARTI and true TB prevalence remains uncertain, and the cost-effectiveness estimates depend on how closely the child immunoreactivity signal tracks adult disease burden. If that relationship weakens, the advantage of geographic targeting shrinks. If it strengthens, the logic of targeted outreach becomes more compelling.
A second layer of uncertainty lies in transmission dynamics. The analysis examined different assumptions about how much active case finding reduces secondary spread, and the results improved when that effect was larger. In practical terms, this reflects the difference between finding a case and interrupting a chain of infection. TB control is never just about the person diagnosed today; it is also about whether one diagnosis prevents the next few cases from emerging in the same neighborhood.
Programmatic adoption will depend on the cost of collecting the signal
The modeling framework points to a workable public health strategy, but not a free one. The authors concluded that Mtb immunoreactivity surveys could substantially improve the health impact and cost-effectiveness of active case finding compared with untargeted approaches, provided that low-cost methods exist to collect those data at scale. Without inexpensive surveillance, the targeting mechanism may be too cumbersome for routine use in high-burden settings.
This is where implementation questions become decisive. A surveillance tool that is epidemiologically elegant but operationally expensive will struggle in settings where every additional field visit competes with case management, treatment support, and routine diagnostic work. The value of ARTI-guided targeting will depend on whether the surveys can be repeated, interpreted, and translated into neighborhood-level deployment decisions quickly enough to matter for control efforts.
The study does not answer whether the approach will outperform standard practice in real-world program conditions. It does show that, in a modeled urban TB epidemic, concentrating outreach where child immunoreactivity is highest can preserve most of the case-finding yield while reducing the number of people who need to be screened. The remaining question is not whether targeting makes theoretical sense, but whether health systems can measure ARTI cheaply enough to use it as a routine guide for TB outreach.